Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy: A report of 2 cases Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Neurotoxicity Syndromes

abstract

  • Two patients with recurrent lymphoma developed an acute, transient encephalopathy following administration of recombinant human granulocyte-colony stimulating factor (rhG-CSF), filgrastim, in anticipation of leukapheresis for hematopoietic stem cell transplantation. Head magnetic resonance imaging showed evidence of blood-brain barrier (BBB) breakdown, compatible with posterior reversible encephalopathy syndrome (PRES). The proposed pathogenesis of PRES was rhG-CSF-induced neutrophil mobilization and activation with the release of inflammatory mediators, resulting in transient alteration of barrier permeability and capillary leakage.

publication date

  • October 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jns.2012.07.028

PubMed ID

  • 22846793

Additional Document Info

start page

  • 35

end page

  • 8

volume

  • 321

number

  • 1-2